Annual EBITDA
-$46.06 M
-$12.99 M-39.29%
December 31, 2023
Summary
- As of February 26, 2025, SCPH annual EBITDA is -$46.06 million, with the most recent change of -$12.99 million (-39.29%) on December 31, 2023.
- During the last 3 years, SCPH annual EBITDA has fallen by -$16.84 million (-57.62%).
- SCPH annual EBITDA is now -338.09% below its all-time high of -$10.51 million, reached on December 31, 2015.
Performance
SCPH EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$33.26 M
-$18.35 M-123.13%
September 30, 2024
Summary
- As of February 26, 2025, SCPH quarterly EBITDA is -$33.26 million, with the most recent change of -$18.35 million (-123.13%) on September 30, 2024.
- Over the past year, SCPH quarterly EBITDA has dropped by -$22.14 million (-199.27%).
- SCPH quarterly EBITDA is now -766.92% below its all-time high of -$3.84 million, reached on December 31, 2016.
Performance
SCPH Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$71.23 M
-$19.68 M-38.18%
September 30, 2024
Summary
- As of February 26, 2025, SCPH TTM EBITDA is -$71.23 million, with the most recent change of -$19.68 million (-38.18%) on September 30, 2024.
- Over the past year, SCPH TTM EBITDA has dropped by -$25.36 million (-55.30%).
- SCPH TTM EBITDA is now -1756.80% below its all-time high of -$3.84 million, reached on December 31, 2016.
Performance
SCPH TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SCPH EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -39.3% | -199.3% | -55.3% |
| 3 y3 years | -57.6% | -363.9% | -115.4% |
| 5 y5 years | -66.4% | -363.9% | -115.4% |
SCPH EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -84.1% | at low | -404.9% | at low | -184.7% | at low |
| 5 y | 5-year | -84.1% | at low | -476.0% | at low | -184.7% | at low |
| alltime | all time | -338.1% | at low | -766.9% | at low | -1756.8% | at low |
ScPharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$33.26 M(+123.1%) | -$71.23 M(+38.2%) |
| Jun 2024 | - | -$14.90 M(+24.7%) | -$51.55 M(+5.9%) |
| Mar 2024 | - | -$11.96 M(+7.6%) | -$48.68 M(+6.1%) |
| Dec 2023 | -$46.06 M(+39.3%) | -$11.11 M(-18.1%) | -$45.87 M(+9.4%) |
| Sep 2023 | - | -$13.57 M(+12.8%) | -$41.92 M(+10.3%) |
| Jun 2023 | - | -$12.04 M(+31.6%) | -$38.02 M(+8.3%) |
| Mar 2023 | - | -$9.14 M(+27.5%) | -$35.10 M(+6.1%) |
| Dec 2022 | -$33.07 M(+32.2%) | -$7.17 M(-25.8%) | -$33.07 M(+1.8%) |
| Sep 2022 | - | -$9.67 M(+6.0%) | -$32.49 M(+13.6%) |
| Jun 2022 | - | -$9.12 M(+28.3%) | -$28.59 M(+10.9%) |
| Mar 2022 | - | -$7.11 M(+8.0%) | -$25.77 M(+3.0%) |
| Dec 2021 | -$25.02 M(-14.4%) | -$6.59 M(+14.1%) | -$25.02 M(-1.7%) |
| Sep 2021 | - | -$5.77 M(-8.4%) | -$25.46 M(-9.0%) |
| Jun 2021 | - | -$6.30 M(-0.9%) | -$27.97 M(-4.3%) |
| Mar 2021 | - | -$6.36 M(-9.4%) | -$29.22 M(-0.0%) |
| Dec 2020 | -$29.22 M | -$7.02 M(-15.2%) | -$29.22 M(-9.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$8.28 M(+9.6%) | -$32.27 M(+8.6%) |
| Jun 2020 | - | -$7.56 M(+18.8%) | -$29.71 M(+2.6%) |
| Mar 2020 | - | -$6.36 M(-36.9%) | -$28.95 M(-6.2%) |
| Dec 2019 | -$30.86 M(+11.5%) | -$10.07 M(+76.2%) | -$30.86 M(+21.3%) |
| Sep 2019 | - | -$5.72 M(-15.9%) | -$25.43 M(+1.6%) |
| Jun 2019 | - | -$6.80 M(-17.9%) | -$25.04 M(-9.4%) |
| Mar 2019 | - | -$8.28 M(+78.2%) | -$27.65 M(-0.1%) |
| Dec 2018 | -$27.68 M(+21.1%) | -$4.64 M(-12.6%) | -$27.68 M(-6.2%) |
| Sep 2018 | - | -$5.32 M(-43.5%) | -$29.50 M(+0.7%) |
| Jun 2018 | - | -$9.41 M(+13.2%) | -$29.31 M(+11.5%) |
| Mar 2018 | - | -$8.31 M(+28.5%) | -$26.28 M(+15.0%) |
| Dec 2017 | -$22.85 M(+28.6%) | -$6.46 M(+26.1%) | -$22.85 M(+13.0%) |
| Sep 2017 | - | -$5.13 M(-19.6%) | -$20.23 M(+33.9%) |
| Jun 2017 | - | -$6.38 M(+30.5%) | -$15.10 M(+73.1%) |
| Mar 2017 | - | -$4.89 M(+27.4%) | -$8.72 M(+127.4%) |
| Dec 2016 | -$17.77 M(+69.0%) | -$3.84 M | -$3.84 M |
| Dec 2015 | -$10.51 M | - | - |
FAQ
- What is scPharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for scPharmaceuticals?
- What is scPharmaceuticals annual EBITDA year-on-year change?
- What is scPharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for scPharmaceuticals?
- What is scPharmaceuticals quarterly EBITDA year-on-year change?
- What is scPharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for scPharmaceuticals?
- What is scPharmaceuticals TTM EBITDA year-on-year change?
What is scPharmaceuticals annual EBITDA?
The current annual EBITDA of SCPH is -$46.06 M
What is the all time high annual EBITDA for scPharmaceuticals?
scPharmaceuticals all-time high annual EBITDA is -$10.51 M
What is scPharmaceuticals annual EBITDA year-on-year change?
Over the past year, SCPH annual EBITDA has changed by -$12.99 M (-39.29%)
What is scPharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of SCPH is -$33.26 M
What is the all time high quarterly EBITDA for scPharmaceuticals?
scPharmaceuticals all-time high quarterly EBITDA is -$3.84 M
What is scPharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, SCPH quarterly EBITDA has changed by -$22.14 M (-199.27%)
What is scPharmaceuticals TTM EBITDA?
The current TTM EBITDA of SCPH is -$71.23 M
What is the all time high TTM EBITDA for scPharmaceuticals?
scPharmaceuticals all-time high TTM EBITDA is -$3.84 M
What is scPharmaceuticals TTM EBITDA year-on-year change?
Over the past year, SCPH TTM EBITDA has changed by -$25.36 M (-55.30%)